Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jan;68(1):121-130.
doi: 10.1007/s00262-018-2257-2. Epub 2018 Oct 10.

Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer

Wen Zhang  1 , Xu Lu  2 , Peilin Cui  3 , Chunmei Piao  4 , Man Xiao  5 , Xuesong Liu  2 , Yue Wang  2 , Xuan Wu  2 , Jingwei Liu  6 , Lin Yang  7
Affiliations
Clinical Trial

Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer

Wen Zhang et al. Cancer Immunol Immunother. 2019 Jan.

Abstract

Dendritic cell (DC)-based immunotherapies have been created for a broad expanse of cancers, and DC vaccines prepared with Wilms' tumor protein 1 (WT1) peptides have shown great therapeutic efficacy in these diseases. In this paper, we report the results of a phase I/II study of a DC-based vaccination for advanced breast, ovarian, and gastric cancers, and we offer evidence that patients can be effectively vaccinated with autologous DCs pulsed with WT1 peptide. There were ten patients who took part in this clinical study; they were treated biweekly with a WT1 peptide-pulsed DC vaccination, with toxicity and clinical and immunological responses as the principal endpoints. All of the adverse events to DC vaccinations were tolerable under an adjuvant setting. The clinical response was stable disease in seven patients. Karnofsky Performance Scale scores were enhanced, and computed tomography scans revealed tumor shrinkage in three of seven patients. Human leukocyte antigen (HLA)/WT1-tetramer and cytoplasmic IFN-γ assays were used to examine the induction of a WT-1-specific immune response. The immunological responses to DC vaccination were significantly correlated with fewer myeloid-derived suppressor cells (P = 0.045) in the pretreated peripheral blood. These outcomes offered initial clinical evidence that the WT1 peptide-pulsed DC vaccination is a potential treatment for advanced cancer.

Keywords: Cytotoxic T lymphocytes; Dendritic cell; Immunotherapy; Tumor-associated antigens; WT1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Frequency of WT1-specific CTLs before and after DC vaccination in the tetramer assay. The black horizontal bar shows the median. Differences between values before and after WT1 vaccination were statistically significant (P < 0.05)
Fig. 2
Fig. 2
WT1-specific CTLs induced by DC vaccination. a Upper panel, WT1-peptide/HLA-A*2402 tetramer assays. Percentages represent the frequency of tetramer+CD8+ T cells. Cases 1, 3, 7, and 8 show a significant increase in the frequency of tetramer+CD8+ T cells after DC vaccination compared to pre-therapy (*P < 0.05). b Lower panel, IFN-γ-producing clones in ELISPOT assays with WT1 peptide. Cases 1, 3, 7, and 8 show a significant increase in the response in the ELISPOT after DC vaccination compared to pre-therapy values (*P < 0.05)
Fig. 3
Fig. 3
Tumor regression occurred in patient 3 a with metastatic breast cancer and in patient 7 b with ovarian cancer during the course of DC vaccination. (Left) Before and (right) after DC vaccination, respectively. Arrows indicate the presumed location of the tumor
Fig. 4
Fig. 4
Pretreatment total lymphocyte numbers and the frequency of various circulating lymphocyte phenotypes in the peripheral blood of all patients. The immunological responses were significantly correlated with fewer myeloid-derived suppressor cells (MDSCs). MDSCs were identified as CD14−CD11b+CD33+. IR, immunological responses
See this image and copyright information in PMC

References

    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Sci. 2013;342:1432–1433. doi: 10.1126/science.342.6165.1432. - DOI - PubMed
    1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–5337. doi: 10.1158/1078-0432.CCR-09-0737. - DOI - PMC - PubMed
    1. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, Abeno S, Tatsumi N, Yokota A, Aoyagi S, Nakazawa T, Ito K, Kanato K, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Aozasa K, Yoshimine T, Sugiyama H. Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors. Cancer Sci. 2004;95:822–827. doi: 10.1111/j.1349-7006.2004.tb02188.x. - DOI - PMC - PubMed
    1. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541–6548. doi: 10.1182/blood-2009-02-202598. - DOI - PubMed
    1. Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M, Nishida S, Morimoto S, Murao A, Nakajima H, Hosen N, Oji Y, Sugiyama H. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia. 2012;26:1410–1413. doi: 10.1038/leu.2011.343. - DOI - PubMed

Publication types